APA (7th ed.) Citation

SW, H., KC, L., LC, G., Y, Y., S, S., P, S., . . . A, R. (2017). The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. Neoplasia (New York, N.Y.), 19(9), 661. https://doi.org/10.1016/j.neo.2017.06.001

Chicago Style (17th ed.) Citation

SW, Hicks, et al. "The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models." Neoplasia (New York, N.Y.) 19, no. 9 (2017): 661. https://doi.org/10.1016/j.neo.2017.06.001.

MLA (9th ed.) Citation

SW, Hicks, et al. "The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models." Neoplasia (New York, N.Y.), vol. 19, no. 9, 2017, p. 661, https://doi.org/10.1016/j.neo.2017.06.001.